-
Many cities in Guangdong have launched free HPV vaccination for school-age girls
Time of Update: 2022-09-20
According to the "Guangdong Provincial Work Plan for Free Human Papillomavirus (HPV) Vaccination for School-age Girls (2022-2024)", the plan plans to enhance the awareness of cervical cancer prevention and control in target populations, improve the health level of women in the province, reduce the prevalence of cervical cancer, and gradually achieve 90% of girls under 15 years old to complete hpV preventive vaccine immunization by 2030.
-
The operating area is not less than 100㎡! Is it getting harder and harder to apply for a designated pharmacy?
Time of Update: 2022-09-20
01 Henan Medical Insurance Bureau: "Non-medical insurance card" area is less than 20% The "Plan" divides the assessment work of designated pharmacies into two forms of assessment, written and on-site, covering a total of 9 types of inspection items, involving whether the written materials are consistent with the actual situation, practicing pharmacist qualification certificates and labor contracts, and drug purchase, sale and inventory management.
-
The development of the out-of-hospital market has become the focus of the development of pharmaceutical companies and circulation enterprises!
Time of Update: 2022-09-20
In recent years, with the continuous implementation of medical reform measures such as medical insurance cost control, centralized procurement, zero addition of drugs in hospitals, and outflow of prescriptions, the original domestic pharmaceutical circulation pattern has been broken, and the layout has become the consensus of pharmaceutical companies in the off-hospital market.
-
The development of new drugs has accelerated, and recent clinical trials of many drugs have ushered in new progress
Time of Update: 2022-09-20
The clinical trial of BUCHANG Pharmaceutical BC008-1A injection drug was approved Recently, Buchang Pharmaceutical announced that its subsidiary has obtained a notice of approval for clinical trials of BC008-1A injection drugs, and the main indication of the drug is advanced solid tumor.
-
Notice of Public Solicitation of Recommendations for the Implementation of the ICH Q3D(R2): Guiding Principles on Elemental Impurities and Chinese Edition
Time of Update: 2022-09-20
Q3D (R2) English version Drug Evaluation Center of the State Drug Administration September 8, 2022 In order to promote the smooth implementation of the newly revised ICH guidelines in China, our center has formulated the implementation recommendations of "Q3D (R2): Guiding Principles for Elemental Impurities" and organized the translation of Chinese version.
-
Fosun Pharma was the first to reduce its holdings, but the pharmaceutical business grew against the trend, can it revitalize its glory in the future?
Time of Update: 2022-09-20
This is fosun pharma's third largest equity acquisition transaction in the past 10 years, in 2020 and 2021, BioNTech stock price increased by 140% and 216% respectively due to the new crown epidemic, and as of the end of 2021, this investment has brought more than 2.
-
Read it in one article: the specific differences between CRO, CMO, and CDMO
Time of Update: 2022-09-20
The various services provided by the company and their relationship with the final product are as follows: The main goal of the CDMO services provided by the company to customers is to successfully develop products such as pharmaceutical intermediates or APIs with commercial production feasibility in accordance with customer requirements.
-
Beijing biomedical whole industry chain open in the first half of the year approved innovative drugs and other national first
Time of Update: 2022-09-20
The "Implementation Plan for the Opening Up of the Whole Industry Chain of Biomedicine in Beijing" released at the beginning of this year put forward 17 50 policy measures and suggestions to accelera
-
Npc deputies suggested that the cost of dental treatment be included in medical insurance The National Medical Insurance Bureau replied
Time of Update: 2022-09-20
Pharmaceutical The National Medical Security Bureau recently released on its official website its reply to Recommendation No. 3946 of the Fifth Session of the 13th National People's Congress (hereinafter referred to as the "Reply").
-
Chinese Medicine Innovation Dragon Hair Wei! 3 exclusive proprietary Chinese medicines sold for 10 billion
Time of Update: 2022-09-20
2019H1-2022H1 R&D investment of Yiling Pharmaceutical (: 100 million yuan) Source: Company Announcement Since 2020, 16 new Chinese medicine drugs (in terms of drug name + enterprise, excluding APIs) have been approved for listing, covering anti-tumor, respiratory system, nervous system, gynecology, orthopedics and other therapeutic fields.
-
Hubei is expected to become a national center for the collection and collection of proprietary Chinese medicines! 42 proprietary Chinese medicines will soon be collected
Time of Update: 2022-09-20
By combining five major innovations, such as generic name procurement, comprehensive scoring shortlisting, combination of intra-product competition and inter-product competition to break the bid-rigging, introducing medical institution recognition indicators, and the lowest daily average treatment cost can be selected, the collection system solved the difficulties of collection and collection such as the difficulty of evaluating the quality of proprietary Chinese medicines and the unique products of proprietary Chinese medicines.
-
The innovation and upgrading of pharmaceutical enterprises has become the trend of the times, but these "shortcomings" still need to be filled
Time of Update: 2022-09-20
In addition, from the 2022 innovative drug enterprise report, more than 70% of the innovative pharmaceutical companies have increased their R&D investment, such as BeiGene, Hengrui, Junshi Biological, China Biopharmaceuticals, CSPC Pharmaceutical Research and Development, and Huang Pharmaceutical, which have invested more than 1 billion yuan.
-
China's annual production capacity of COVID-19 vaccines exceeds 7 billion doses, and the output exceeds 5.5 billion doses
Time of Update: 2022-09-20
(End) According to data disclosed by The Ministry of Industry and Information Technology of China on the 14th, China's annual production capacity of the new crown virus vaccine exceeds 7 billion doses and the output exceeds 5.
-
Tianzhi Granule Clinical Release Expert Consensus and National Lecture Tour Kick-off Meeting was held in Beijing
Time of Update: 2022-09-15
Sponsored by the Beijing Neurology Society and co-organized by the Tianzhi Alliance for the Prevention and Treatment of Brain Dysfunction, the "Expert Consensus on the Clinical Application of Tianzhi
-
National Health Commission: By the end of 2021, there are nearly 980,000 primary medical and health institutions nationwide
Time of Update: 2022-09-14
On September 7, the Propaganda Department of the CPC Central Committee held a series of press conferences on the theme of "China's Decade" to introduce the achievements in the development of health care since the 18th National Congress of the Communist Party of China and answer reporters' questions.
-
The continuous growth of the income of the Chinese medicine industry has promoted the acceleration of strategic adjustment and upgrading of Chinese medicine enterprises
Time of Update: 2022-09-14
For example, among the listed Chinese medicine companies that disclosed their 2021 annual reports, more than half of the R&D investment of enterprises achieved year-on-year growth.
For example, among the listed Chinese medicine companies that disclosed their 2021 annual reports, more than half of the R&D investment of enterprises achieved year-on-year growth.
-
Since the beginning of this year, many pharmaceutical companies have been fined for environmental protection problems!
Time of Update: 2022-09-14
On February 9, 2022, Xinhua Pharmaceutical was fined 132,000 yuan by the Zibo Municipal Bureau of Ecology and Environment, and fined a total of 253,800 yuan for two environmental protection issues because it violated Article 18 of the Regulations on the Administration of Pollution Discharge Permits because the pollutant discharge methods and discharge destinations did not match the discharge permits.
-
Under the continuous investment in research and development, the income of many pharmaceutical companies in innovative drugs has reached a new high!
Time of Update: 2022-09-14
【Pharmaceutical Network Industry News】At present, the 2022 interim report of listed pharmaceutical companies has been disclosed one after another, and it can be seen from the reports of many pharmaceutical companies that through continuous investment in research and development, a number of pharmaceutical companies have achieved great results in innovative drugs, driving high revenue growth in the first half of the year.
-
Pharmaceutical companies have performed well, but the secondary market has performed coldly, is the CXO sector still worth paying attention to?
Time of Update: 2022-09-14
In the first half of this year, the CXO sector can be said to be a track against the trend in the pharmaceutical subdivision sector, the growth momentum is rapid, as of August 30, A shares have disclosed that among the 29 CXO listed companies reported in the report, more than 70% of the net profit increased year-on-year, of which Boteng shares and Gloria Ying the two companies' revenue and profits have doubled.
-
By 2021, the total number of health personnel in China will reach 13.983 million
Time of Update: 2022-09-14
At the "China Decade" series of theme press conferences held on September 7, Li Bin, deputy director of the National Health Commission, introduced that since the Eighteenth National Congress of the Communist Party of China, the prevention and control of infectious diseases, chronic diseases, occupational diseases and endemic diseases in China has been more effective and powerful, the overall quality of the health talent team has been continuously improved, and the medical technology ability and quality level have been improved.
